Immune impacts of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia patients: are we closer to a holy grail?

Leuk Lymphoma. 2020 Oct;61(10):2283-2285. doi: 10.1080/10428194.2020.1811865. Epub 2020 Sep 8.

Authors

Sasanka M Handunnetti^{1

2}, Constantine S Tam^{1

3}

Affiliations

¹ Clinical Haematology Department, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.
² Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.
³ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.

PMID: 32900243
DOI: 10.1080/10428194.2020.1811865

No abstract available

Publication types

Comment

MeSH terms

Humans
Immunity, Humoral
Infections*
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Patients
Protein Kinase Inhibitors / adverse effects

Substances

Protein Kinase Inhibitors